Biomarkers for Preclinical Alzheimer’s Disease -

Biomarkers for Preclinical Alzheimer’s Disease

Robert Perneczky (Herausgeber)

Buch | Hardcover
272 Seiten
2018 | 1st ed. 2018
Humana Press Inc. (Verlag)
978-1-4939-7673-7 (ISBN)
53,49 inkl. MwSt
Jetzt zum Sonderpreis
Listenpreis (bisher): 101,64 €
This volume discusses the importance of imaging, fluid, and genetic biomarkers in detecting the earliest pre-symptomatic stages of Alzheimer’s disease (AD). Parts four and five talk about technological advancements in AD diagnosis and ethical considerations in AD research.
This volume discusses the importance of imaging, fluid, and genetic biomarkers in detecting the earliest pre-symptomatic stages of Alzheimer’s disease (AD). The chapters in this book are separated into five parts. Part one explores the reasons why we need improved approaches for early detection and diagnosis of AD. Part two describes clinical and research techniques for preclinical AD diagnosis. Part three looks at the current methods in use to diagnose AD and how they can also be used for early detection in healthy older individuals. Parts four and five talk about technological advancements in AD diagnosis and ethical considerations in AD research. In Neuromethods series style, chapters include the kind of detail and key advice from the specialists needed to get successful results in your laboratory.

Comprehensive and cutting-edge, Biomarkers for Preclinical Alzheimer’s Disease is a valuable resource for individuals interested in the use of biomarker strategies to improve early AD detection. This book will be of great interest to researchers and clinicians from both academia and industry.”

Worldwide Economic Costs and Societal Burden of Dementia.- Epidemiology and Risk Factors of Alzheimer’s Disease: A Focus on Diet.- The Dimensional Structure of Subjective Cognitive Decline.- Deriving and Testing the Validity of Cognitive-Reserve Candidates.- Methods for Pathological Classification of Alzheimer’s Disease.- Cerebrospinal Fluid Biomarkers of Preclinical Alzheimer’s Disease.- Brain Structural Imaging in Alzheimer’s Disease.- Brain Functional Imaging in Preclinical Alzheimer’s Disease.- Imaging of Brain Amyloid Load in Early Alzheimer’s Disease.- Functional EEG Connectivity Alterations in Alzheimer’s Disease.- A Selected Reaction Monitoring Protocol for the Measurement of sTREM2 in Cerebrospinal Fluid.- Soluble Amyloid Precursor Proteins in Blood: Methods and Challenges.- Tau Imaging in Preclinical Alzheimer’s Disease.- Retinal Imaging in Early Alzheimer’s Disease.- In Vivo Volumetry of the Cholinergic Basal Forebrain.- Clinical Meaningfulness of Biomarkers Endpoints in Alzheimer’s Disease Research.- The Ethics of Biomarker-Based Preclinical Diagnosis of Alzheimer’s Disease.- Shared Decision-Making and Important Medical and Social Decisions in the Context of Early Diagnosis of Alzheimer’s Disease.

Erscheinungsdatum
Reihe/Serie Neuromethods ; 137
Zusatzinfo 33 Illustrations, color; 6 Illustrations, black and white; XIII, 272 p. 39 illus., 33 illus. in color.
Verlagsort Totowa, NJ
Sprache englisch
Maße 178 x 254 mm
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Geriatrie
Medizin / Pharmazie Studium
Naturwissenschaften Biologie Humanbiologie
Naturwissenschaften Biologie Zoologie
Schlagworte Biomarkers • epidemiology • fluid markers • Imaging • Tau imaging
ISBN-10 1-4939-7673-7 / 1493976737
ISBN-13 978-1-4939-7673-7 / 9781493976737
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
Das Wichtigste für Ärztinnen und Ärzte aller Fachrichtungen

von Klaus Hager; Olaf Krause

Buch | Softcover (2021)
Urban & Fischer in Elsevier (Verlag)
37,00

von Gisela Mötzing; Susanna Schwarz

Buch | Softcover (2022)
Urban & Fischer in Elsevier (Verlag)
33,00
Zukunftssicherheit der Geriatrie - Konzept und Bedarfszahlen

von Bundesverband Geriatrie e.V.

Buch | Softcover (2023)
Kohlhammer (Verlag)
36,00